About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 387023, 8 pages
http://dx.doi.org/10.1155/2013/387023
Review Article

Chitin, Chitosan, and Glycated Chitosan Regulate Immune Responses: The Novel Adjuvants for Cancer Vaccine

1Department of Oncology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
2Department of Gastroenterology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
3Department of Laser Medicine, Chinese PLA General Hospital, Beijing 100853, China
4ImmunoPhotonics Inc., Columbia, MO 65211, USA
5Dermatology Associates of San Antonio, San Antonio, TX 78233, USA
6Department of Engineering and Physics, University of Central Oklahoma, Edmond, OK 73034, USA

Received 12 September 2012; Revised 22 December 2012; Accepted 26 December 2012

Academic Editor: Clelia M. Riera

Copyright © 2013 Xiaosong Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

With the development of cancer immunotherapy, cancer vaccine has become a novel modality for cancer treatment, and the important role of adjuvant has been realized recently. Chitin, chitosan, and their derivatives have shown their advantages as adjuvants for cancer vaccine. In this paper, the adjuvant properties of chitin and chitosan were discussed, and some detailed information about glycated chitosan and chitosan nanoparticles was also presented to illustrate the trend for future development.